Concepedia

Takaaki Fujimura

TF

Statistics

Publications

5

Citations

89

H-Index

5

Active since

2016

Affiliations

Chugai Pharma (United States)(Current)

Takaaki Fujimura is an author at Chugai Pharma (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

2016–2023

5

Publications

5

Development of a stable ERroGFP variant suitable for monitoring redox dynamics in the ER

Jun Hoseki, Asami Oishi, Takaaki Fujimura et al. · Bioscience Reports · 2016 · 29 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate

Yoriko Yamashita‐Kashima, Yasushi Yoshimura, Takaaki Fujimura et al. · Cancer Chemotherapy and Pharmacology · 2019 · 19 citations

Medicine, Oncology, Pharmacology +17

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes

Koh Furugaki, Takaaki Fujimura, Hayato Mizuta et al. · npj Precision Oncology · 2023 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17

Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells

Takaaki Fujimura, Yoriko Yamashita‐Kashima, Natsumi Kawasaki et al. · Molecular Cancer Therapeutics · 2021 · 13 citations · Full text

Medicine, Immunology, Oncology +17

Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies

Natsumi Kawasaki, Yoriko Yamashita‐Kashima, Takaaki Fujimura et al. · Molecular Biology Reports · 2022 · 11 citations · Full text

Medicine, Immunology, Pharmacology +17

1–5 of 5